<DOC>
	<DOCNO>NCT01580488</DOCNO>
	<brief_summary>The purpose study evaluate anti-psoriatic effect LEO 35299 different formulation , compare Daivonex® ointment Daivonex® ointment vehicle , use psoriasis plaque test modify method develop KJ Dumas JR Scholtz .</brief_summary>
	<brief_title>A Plaque Test Study With LEO 35299 Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Following verbal write information trial , subject must provide sign date informed consent study related activity carry . 2 . Age 18 year . 3 . Males , female nonchild bear potential . 4 . Subjects , opinion investigator , stable psoriasis base Total Plaque Score evaluate screen visit visit 2 ( Baseline ) . 1 . Male subject willing use local contraception ( condom ) time study entry three month follow last study drug application . 2 . Female subject pregnant , childbearing potential breast feeding . 3 . Systemic treatment biological therapy ( market market ) possible effect psoriasis vulgaris within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 weeks/5 halflives ( whichever islonger ) experimental biological product prior randomisation study . 4 . Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immune suppressant ) within 4week period prior randomisation study . 5 . Subjects use one follow topical drug treatment psoriasis within 4 week period prior randomisation study : Potent potent ( WHO group IIIIV ) corticosteroid . 6 . Subjects use phototherapy within follow time period prior randomisation study : PUVA ( 4 week ) UVB ( 2 week ) 7 . Subjects use one follow topical drug treatment psoriasis within two week prior randomisation study : WHO group III corticosteroid ( except use treatment scalp and/or facial psoriasis ) Topical retinoids Vitamin D analogues Topical immunomodulators ( e.g . macrolides ) Anthracen derivative Tar , Salicylic acid . 8 . Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis 9 . Subjects known/suspected disorder calcium metabolism associate hypercalcemia within last 10 year , base medical history and/or subject interview 10 . Subjects receive treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4 week period prior randomisation longer , class substance require long washout define ( e.g. , biological treatment ) 11 . Subjects current participation interventional clinical , base interview subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>